Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model
K Hopp, CJ Hommerding, X Wang, H Ye… - Journal of the …, 2015 - journals.lww.com
Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of ESRD. A
central defect associated with ADPKD pathology is elevated levels of 3′, 5′-cyclic AMP
(cAMP). Compounds such as tolvaptan and pasireotide, which indirectly reduce adenylyl
cyclase 6 (AC6) activity, have hence proven effective in slowing cyst progression. Here, we
tested the efficacy of these compounds individually and in combination in a hypomorphic
PKD1 model, Pkd1 R3277C/R3277C (Pkd1 RC/RC), in a 5-month preclinical trial. Initially …
central defect associated with ADPKD pathology is elevated levels of 3′, 5′-cyclic AMP
(cAMP). Compounds such as tolvaptan and pasireotide, which indirectly reduce adenylyl
cyclase 6 (AC6) activity, have hence proven effective in slowing cyst progression. Here, we
tested the efficacy of these compounds individually and in combination in a hypomorphic
PKD1 model, Pkd1 R3277C/R3277C (Pkd1 RC/RC), in a 5-month preclinical trial. Initially …